Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr Janelle Davidson of Marietta Georgia announced she is opening her practice. She replied to Kyke Klute's post that she just completed her CLIA Lab Director courses and is adding #TPOC diagnostic tests.
Her office is a New Customer somewhere in the pipeline. In my opinion Q2 sales should tell us a lot about AXIM's revenue growth expectations.
https://www.linkedin.com/posts/dr-janelle-davison-028aa824_visionarydryeyeinstitute-dryeyerelief-grandopening-ugcPost-7193243599470239744-3ugB?utm_source=share&utm_medium=member_android
Not investment advice.
Verséa is listed as manufacturer in this article from a few days ago. The authors appear to teach at Ophthalmology medical schools in Miami and Toronto.
https://www.ophthalmologymanagement.com/issues/2024/may/dry-eye-diagnostics-in-real-time-practice/
At least the tests are getting name recognition.
A Third thing I noticed about this post is that Jessica Barr is not mentioned. This new customer called out "Thank you" to Kerry Robbers and Rahim Hirji. I believe Rahim Hirji has past work experience and his current title of "VP Marketing, Clinical Training and Implementation" would imply that he is qualified to "Approve" that a new customer has met the CLIA standards and requirements and can start selling the new AXIM Diagnostics tests.
If this turns out to be true, then we may see more than one new customer added per week. If Rahim Hirji becomes the second person on the Verséa Ophthalmics staff that is allowed to approve a CLIA compliance certification then time to cashflow positive for AXIM is cut in half.
THREE Takeaways from this post by a new customer:
In my opinion a case can be made that there is a significant backlog of new customers in the process of becomming CLIA Compliant. This eye doctor appears to have taken the steps to become CLIA compliant.
Now we know that Eye Doctors can take an online self-paced course to become CLIA compliant as a Lab Director.
And the third thing we learned from this post is that Jessica Barr might have some help from VP Rahim Hirji to certify a new customer.
Good luck to all.
Not investment advice.
Reread this post and the replies to this post. A second AXIM/Verséa customer replied to the post and mentioned she just completed the Lab Director Certification.
There are self-paced Lab Director courses available online. Here is a link.
https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments/training
Quote:
"The courses listed below are designed to meet the Clinical Laboratory Improvement Amendments (CLIA) requirement at 42 CFR 493.1405(b)(2)(ii)(B)."
This certification might be a requirement before Verséa Ophthalmics sends a person to verify CLIA compliance.
RE: Btw, I have not seen an "official announcement" about this customer from the Verséa Ophthalmics LinkedIn page.
This is the basis of my opinion about significant backlogs within the sale channel.
From the July 2023 AXIM Press Release about manufacturing and shipping Diagnostics tests and the five months of silence until the December 20th 2023 Press Release about manufacturing partner Auer Precision I believe there was a growing backlog of sales demand that was not getting filled.
After the Auer Precision announcement or around the same time, we started seeing the #TPOCTITAN announcements on the Verséa Ophthalmics LinkedIn page. About one announcement a week since the first one.
This new customer has not been officially announced yet. Are they "CLIA Certified". I think I have seen a prior post that they are CLIA Certified. But they have not been announced as a #TPOCTITAN.
There may be significant backlogs at every stage of the new customer sales channel.
Just my opinion.
Not investment advice.
LinkedIn post by a new customer.
https://www.linkedin.com/posts/kyledkluteod_optometrists-dryeye-eyecare-activity-7193277260458594304-UOAG?utm_source=share&utm_medium=member_android
Btw, I have not seen an "official announcement" about this customer from the Verséa Ophthalmics LinkedIn page.
ARVO-2024
Verséa Health (Verséa Ophthalmics) has booth MS6 at ARVO 2024 in Seattle May 5-9.
It sure seems like something changed at the beginning of April. Not just the corporate address but the lack of communication on the LinkedIn Verséa Ophthalmics page. I subscribe to the ARVO posts on LinkedIn. Noticed today the 2024 ARVO meeting in Seattle and searched their website for Verséa.
Found them on the Exhibitors list here:
https://events.ntpshow.com/ARVO2024/Public/exhibitors.aspx
They are obviously going to the meeting.
They have a booth at the meeting.
Posts on LinkedIn seem to be Free.
So far no announcement from Verséa about being at ARVO 2024. Maybe they are just too busy to post updates??
Meeting website
https://www.arvo.org/annual-meeting/
I can't believe this is holding a penny. The longer it takes for this company to show results the more it looks like a scam...just my 2 cents
Btw, I do believe there is a backlog of customers waiting for the approval that they are CLIA compliant and can begin selling. One of those eye doctor offices posted on LinkedIn a few weeks ago. I have not yet seen the announcement they are approved and selling the AXIM tests.
In my opinion we will continue to see at least 1 new customer every week until CLIA Waiver Applications have been submitted and approved.
It feels too slow but customers do like how the AXIM test system can help their customers and businesses.
If there truly is a backlog of customers waiting for CLIA compliance training, then my guess is Verséa Ophthalmics will prioritize adding more resources that can help Eye doctor offices get setup and trained as CLIA compliant locations.
There are companies and individuals that provide contract services to help with CLIA compliance training and setup. Hiring more people for that role may not be necessary if CLIA Waivers are submitted and approved sooner rather than later.
Jessica Barr may have the "train the trainers" experience on her resume as well.
At current pace AXIM has gained an average of one new customer per week over the last 4.5 months. The number of existing customers selling AXIM tests may be close to 20 locations at this time. At some point AXIM will provide some sales numbers that can be validated against original expectations.
Until AXIM is cashflow positive someone on the inside is financing the difference to gain an ever larger share of the business.
Good luck to all.
Not investment advice.
Slowly but surely building a solid customer base .. thank you for the update Tex
New customer from Edmond Oklahoma.
BVA Better Vision Ahead.
Appears to be half a dozen eye doctors and just as many locations in that area.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitans-tpoc-osd-activity-7191406107049771009-USgZ?utm_source=share&utm_medium=member_android
BVA Website
https://bva20-20.com/
Hashtags related to AXIM Biotech and business partners.
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
After having a few days to look at the sunbiz.org information about Verséa my impression is that not much has changed.
First the parent company changed their name from Verséa Holdings to Verséa Health.
Second all of the corporate entities changed their address. Current address is about a mile away from previous address.
Third while each division is separated into their own corporate subsidiaries it seems they share resources and are fully owned by the parent company.
Last. Maybe it is not that big a deal to be setup as a Foreign Limited Liability Company? I don't know . I'm not sure what the benefits are.
Just a quick list and 100% opinion.
I was trying not to say the name last night. ;o)
The Verséa companies and the Dr Sambursky connection seem much better skilled dealing with the FDA. Let's hope that continues especially as it relates to the AXIM products.
I stopped speaking of Empowered Dynamics on this board because someone posted evidence that they were dead. I have continued to believe that we would be seeing Rick and Barry in a later scene in the movie. The chance of him losing his own funds on an EUA play appears to be fairly slim. He has been around too long to bankroll a long shot.
What I noticed last night was that Brett Parent has a foundational role with Verséa but looking at LinkedIn he has also had a foundational role in a number of companies associated with Rick Hennessey. So there is a common thread that loosely ties together Verséa and AXIM and Empowered Diagnostics.
I do think having an ISO-13485 certified manufacturer in Auer Precision is much more stable than building a manufacturing company from scratch.
The other Versea divisions are not registered separately. The exist as part of Versea Health.
Time for me to shut down for the night. Sunbiz.org is filled with information.
Then with a little help from LinkedIn.
All the dots seem to be connected to
Brett Parent.
Past and present.
Interesting.
Somehow things are going to work out for AXIM this time.
Thanks for the tip about
Sunbiz.org
I wonder what this means?
What foreign country is first?
When?
Detail by Entity Name
Foreign Profit Corporation
VERSEA OPHTHALMICS, INC.
Filing Information
Document Number. F24000001901
FEI/EIN Number. 88-4015030
Date Filed: 04/05/2024
State. DE
Status. ACTIVE
I believe Dr Sambursky helped Lumos Diagnostics setup a corporate base in Australia.
I'm not sure how many countries they sold products into.
It is good to know that Verséa Ophthalmics has a goal to sell internationally. It seems like the Verséa parent company is growing rapidly. Let's hope the Ophthalmics division grows rapidly as well.
I've been watching Sunbiz and the proliferation of filings by the various components of Versea including the foreign opthalmics subsidiary that is incorporated in Delaware. There is some fancy footwork being exhibited in the dance.
Did anyone else get an email from Verséa a couple of days ago about the change in address?
While searching the new business address I found something very interesting. Use the link below. I have no idea what this means with the relationship with AXIM. Maybe nothing.
Company Age 21 days
"Versea Diagnostics, LLC is a business entity based in Tampa, FL. Established recently on April 5, 2024, this Foreign Limited Liability Company is recognized under the document number M24000004463."
https://www.bizprofile.net/fl/tampa/versea-diagnostics-llc
Cut/Paste of the email below.
Dear Valued Customers and Partners,
We are excited to share that Verséa Health has moved to a new location as part of our ongoing growth and commitment to delivering exceptional service. This move will help us optimize our business operations and enhance our ability to serve you better.
Effective TODAY, our new office address is:
603 E Cass Street, Tampa, FL 33602
Please note that our phone numbers and email addresses remain the same.
Here's what this move means for you:
Shipping and Deliveries: Please update your records with our new address for all future shipments and deliveries to avoid any disruptions.
Billing and Invoices: Kindly ensure that all billing documents and invoices issued after April 24, 2024, reflect our new address.
Communication: We are here to assist you through this transition. If you have any questions or concerns, please feel free to contact us via our usual phone numbers and email addresses.
We are dedicated to making this move as seamless as possible and are working diligently to minimize any potential disruptions to our ongoing projects and collaborations.
Thank you for your continued support and understanding during this exciting time.
We look forward to continuing our valued partnership from our new location and are thrilled about the opportunities this move will bring for all of us!
Best regards,
Sean Fetcho
Founder & CEO
Verséa Health, Inc.
Every one of these articles has links to other articles. This is another one from a year ago.
https://www.statnews.com/2023/04/12/parkinsons-biomarkers-michael-j-fox-foundation/
Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review)
I just read the abstract summary of this study, but other diseases can be diagnosed through tear drops.
https://pubmed.ncbi.nlm.nih.gov/36077520/
Remember back to the video interview of CEO Mr Huemoeller by Benzinga? I think Mr Huemoeller mentioned Alzheimers.
https://finance.yahoo.com/news/video-axim-biotechnologies-ceo-presents-130000171.html
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024...
Six minute video embedded in this article from May 2022. Mark Lew MD discusses why tears can be used for testing for Parkinson Disease.
https://www.neurologylive.com/view/motivations-for-using-tears-confirm-parkinson-disease-diagnosis-mark-lew
Interesting video.
AXIM Press release from September 2023
From Yahoo
https://finance.yahoo.com/news/axim-biotechnologies-develops-first-non-130000370.html
SAN DIEGO,, September 12, 2023--AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solu...
Same press release different source.
https://www.insideprecisionmedicine.com/topics/patient-care/tear-drop-test-is-first-rapid-point-of-care-diagnostic-for-parkinsons-disease/
Michael J Fox foundation reported one year ago in April 13, 2023 about the new biomarker.
The AXIM press release about the new TPOC test for Parkinson Disease was in September 2023 just 6 months after the initial discovery.
In my opinion the TPOC Tear-based Parkinson Disease Point-of-Care test is a really big deal. Hope we hear more news about this test soon.
https://www.michaeljfox.org/news/breaking-news-parkinsons-disease-biomarker-found
TPOC Parkinson Disease test. Tear-based Point-of-Care test. This article is a month old but great summary about the new test developed by AXIM scientists.
https://www.darkdaily.com/?p=46757
Not investment advice.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
#Biovance #Biovance3L
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Blue Skys - Do you think AXIM’s 1st Quarter 2024 revenue will be substantially more than the couple of thousand they’ve brought in thus far with all of the offices they’ve signed up for TPOC? Thanks so much
Maybe people are starting to believe this company is a scam? I know I'm halfway there...but still watching and will jump in of I see a good reason.
Ugh, what is happening to the stock today?
Official announcement of a new customer has been shared from the Verséa Ophthalmics LinkedIn page. The Pearle Vision is from Ohio.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitans-tpoc-optometry-activity-7188507259646156801-odNR?utm_source=share&utm_medium=member_android
According to the Verséa Ophthalmics April 3rd press release this Pearle Vision is one of 68 that signed an exclusive agreement with Verséa Ophthalmics for their #Biovance and #Biovance3L products.
https://www.versea.com/west-point-optical-group-llc-and-versea-ophthalmics-inc-announce-partnership-supply-agreement-for-biovanceand-biovance-3l-ocular/
too bad have some still selling low.
Big volume yesterday. Something must be up. Or maybe a Doctor who really likes the tests?
Another detail I wanted to share from the 10K.
PAGE 14.
"On February 20, 2024, AXIM announced that Verséa™ Ophthalmics, LLC, placed an order for an additional 50 of IUL Lateral Flow Readers."
ONLY 50 READERS????
I realize $2000 per reader adds up quickly.
50 × $2000 = $100,000.
BUT
If AXIM and Verséa were anywhere close to CLIA Waiver approval, they would not order just 50 readers. If CLIA Waiver is anywhere close to approval there would be an order of 300 or 500 or 1000 readers.
Besides that, according to one post or video some customers are purchasing two readers so they can run both tests concurrently to save time.
Look at AXIM realistically.
This company has a lot of potential and hopefully just a few months down the road.
Keep watching.
Hang on to some dry powder.
About the only things to budge AXIM share price in the short-term is a potential merger or acquisition or a new merchandising agreement for the Parkinsons disease test. I do think AXIM has to consider a merchandising agreement for the Parkinsons disease test because they are bleeding too much cash right now.
New customer posted to the Verséa Ophthalmics LinkedIn account.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_welcome-to-dry-eye-center-of-west-virginia-activity-7186431660182097920-_b6D?utm_source=share&utm_medium=member_android
QuickVue® Adenoviral Conjunctivitis Test by Quidel is also listed for sale on the Verséa Ophthalmics website.
Verséa Ophthalmics is building their business.
The AXIM tests are a focal point but not the only line of revenue.
Why has Verséa Ophthalmics been so quiet on LinkedIn recently?
I have to believe the TPOC Tear-based Parkinson Disease Point-of-Care test is a really big deal for Verséa to have exclusive merchandising rights to. In my opinion the marketing agreement for the Parkinson Disease test can bring upfront cash and also revenue $ per test sold.
My guess is the Parkinson Disease test would not be limited to eyecare locations.
Thanks. I figured that the AS was in there somewhere. How could there be a derivative liability for insufficient shares with the new AS?
The copy/paste makes me nervous...zero progress. There is enough going on to where this isn't a scam company like MJNA. However, inability to produce results will yield the same result...crash of share price
Auer Precision was mentioned exactly 1 time.
The Parkinson Disease test was mentioned exactly one time.
Page 30
========
Revenues. $ 39,518
Net loss. $(8,059,682)
Page F4
========
Common stock, $0.0001 par value, 1,000,000,000 shares authorized 245,929,403 and 192,441,917 shares issued and outstanding, respectively.
Page F28
˜========
The Company has authorized 1,000,000,000 shares of common stock, with a par value of $0.0001 per share. As of December 31, 2023, and 2022, the Company had 245,929,403 and 192,441,917 shares of common stock issued and outstanding, respectively.
2023 Transactions:
The Company converted debt of $380,858 including accrued interest of $30,858 in exchange for 22,207,486 shares.
these shares were issued at $0.031 resulting in extinguishment of debt Beneficial conversion payment of interest ($688,432) and Debt modifications / conversions feature worth ($459,522).
Common stock issued under s-1 23,000,000 shares in exchange for cash $514,931.
Common Stock issued stock purchase agreement 7,280,000 in exchange for equipment valued at $72,800 and recorded a loss on issuance of $80,080.
BTW, the two DED tests are in Production. I seriously doubt the scientists are still making patentable improvements to the two tests in 2024 since they are already in Production.
(Sigh)
John
John
John
Just for grins I cut/pasted the CLIA forward looking statement paragraph from 2023 and 2024. At least John remembered to change the year.
Bottom line. Verséa will have to help with the CLIA Waiver or it will not get done.
AXIM Biotechnologies, Inc. - 10K - Annual Report - April 17, 2023
The FDA allows for a CLIA waiver, and we intend to pursue a waiver for both current tests and all future product offerings. Our scientists have been diligently making patentable improvements to the tests which will simplify use by the clinician and enhance likelihood the CLIA waiver approval. We plan to file for the waiver early in the second quarter of 2023 after conducting a fairly simple comparative clinical study. The objective will be to determine whether the AXIM Eye test system has equal or better simplicity than the other forms of diagnostic testing for DED, which we believe is the case. This study is a key component of the filing process with the FDA for a Clinical Laboratory Improvement Amendment (CLIA) Certificate of Waiver. We believe that the acquisition of these FDA 510k cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace.
AXIM BIOTECHNOLOGIES, INC.
FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS
The FDA allows for a CLIA waivers, and we intend to pursue a waiver for both current tests and all future product offerings. Our scientists have been diligently making patentable improvements to the tests which will simplify use by the clinician and enhance likelihood of CLIA waiver approval. We plan to file for the waiver in the second quarter of 2024 after conducting a fairly simple comparative clinical study. The objective will be to determine whether the AXIM Eye test system has equal or better simplicity than the other forms of diagnostic testing for DED, which we believe is the case. This study is a key component of the filing process with the FDA for a Clinical Laboratory Improvement Amendment (CLIA) Certificate of Waiver. We believe that the acquisition of these FDA 510(k) cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace.
This isnawesome to see!
This is a great point.
There was still an insufficient shares derivative liability entry in the balance sheet. That must be a pretty extreme liability if a billion shares doesn't cover it. I didn't see the AS increase addressed. Did anyone see where that was addressed?
FORM 10K "The FDA allows for a CLIA waivers, and we intend to pursue a waiver for both current tests and all future product offerings. Our scientists have been diligently making patentable improvements to the tests which will simplify use by the clinician and enhance likelihood of CLIA waiver approval. We plan to file for the waiver in the second quarter of 2024 after conducting a fairly simple comparative clinical study. The objective will be to determine whether the AXIM Eye test system has equal or better simplicity than the other forms of diagnostic testing for DED, which we believe is the case. This study is a key component of the filing process with the FDA for a Clinical Laboratory Improvement Amendment (CLIA) Certificate of Waiver. We believe that the acquisition of these FDA 510(k) cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace."
I've had my comments about MJNA in the past. Is there a risk that MJNA and AXIM BOD and leadership take AXIM private right before sales really take off? Sure that could happen. Axim could also file for bankruptcy and reorganize.
My cost per share is at an acceptable level.
Bottom line for me is we are not even 4 months removed from the Auer Precision manufacturing agreement. Auer Precision is ISO-13485 certified. Verséa Ophthalmics is run by an eye doctor with a dual expertise in diagnostic testing. We have two FDA cleared 510K tests that are in the marketplace right now.
It makes no sense to sell right now.
Obviously a bug on the website. "Please sign in to see pricing" but if you click the cart icon, the price is visible. This is a bug on the website in my opinion. I'm sure you have to create an account to Purchase these tests. The Account setup process should verify and validate the CLIA compliance status of the account location ordering the product.
The website shows $1125 for IgE tests and Lactoferrin Tests. From the following LinkedIn post there is a picture of a box of 50 tests.
$1125 ÷ 50 = $22.5 per test.
https://www.linkedin.com/posts/kyledkluteod_optometry-optometry-optometrists-activity-7182089642018578432-SGx6?utm_source=share&utm_medium=member_android
Why would Verséa Ophthalmics stop posting updates to their LinkedIn page? I don't know but I hope it is not related to the FDA. These tests can only be used by CLIA compliant offices. By extension my guess is that only a CLIA compliant location will be able to order these tests. Unless there is another bug on the website that allows ordering product with a drop ship without an account setup.
Another reason we need CLIA waivers ASAP.
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.
“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.
An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19. Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment.
Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.
AXIM® Biotech CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”
Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”
AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit www.AXIMBiotech.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |